Vascular Biogenics Ltd (VBLT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vascular Biogenics Ltd (VBLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7595
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for cancer therapy. The company also administers treatment for solid tumor indications, with clinical trials in rGBM, thyroid cancer and ovarian cancer. VBL designs its product to address oncology indications in solid tumors, by the blood vessels required for tumor growth. It also developed programs based proprietary platform technologies including an oncology program and an anti-inflammatory program. VBL is headquartered in Or Yehuda, Israel.

Vascular Biogenics Ltd (VBLT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vascular Biogenics Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Nanocarrier Enters into Licensing Agreement with VBL Therapeutics 11
Equity Offering 12
Vascular Biogenics Raises USD15.5 Million in Private Placement of Shares and Warrants 12
Vascular Biogenics Prices Public Offering of Shares for USD18.7 Million 14
Vascular Biogenics Raises USD24 Million in Private Placement of Shares 15
Vascular Biogenics Raises USD15 Million in Public Offering of Shares and Warrants 16
Vascular Biogenics Raises USD40 Million in IPO 18
Vascular Biogenics Ltd – Key Competitors 20
Vascular Biogenics Ltd – Key Employees 21
Vascular Biogenics Ltd – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 16, 2018: VBL Therapeutics announces second quarter 2018 financial results 23
May 17, 2018: VBL Therapeutics Announces First Quarter 2018 Financial Results 25
Mar 15, 2018: VBL Therapeutics Announces Year End 2017 Financial Results 26
Nov 14, 2017: VBL Therapeutics Announces Third Quarter 2017 Financial Results 27
Aug 14, 2017: VBL Therapeutics Announces Second Quarter 2017 Financial Results 29
May 15, 2017: VBL Therapeutics Announces First Quarter 2017 Financial Results 31
Corporate Communications 33
Jun 15, 2017: VBL Therapeutics Announces Appointment of Dr. Corinne Epperly as U.S. Chief Operating Officer 33
Product News 34
07/10/2018: Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy 34
04/04/2017: VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target 35
Mar 13, 2018: VBL halts pivotal Phase III brain tumour drug trial 36
Clinical Trials 37
Apr 16, 2018: VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR 37
Apr 03, 2017: VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASH 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vascular Biogenics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Vascular Biogenics Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nanocarrier Enters into Licensing Agreement with VBL Therapeutics 11
Vascular Biogenics Raises USD15.5 Million in Private Placement of Shares and Warrants 12
Vascular Biogenics Prices Public Offering of Shares for USD18.7 Million 14
Vascular Biogenics Raises USD24 Million in Private Placement of Shares 15
Vascular Biogenics Raises USD15 Million in Public Offering of Shares and Warrants 16
Vascular Biogenics Raises USD40 Million in IPO 18
Vascular Biogenics Ltd, Key Competitors 20
Vascular Biogenics Ltd, Key Employees 21

List of Figures
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vascular Biogenics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vascular Biogenics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Vascular Biogenics Ltd (VBLT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Xbrane Biopharma AB (XBRANE):製薬・医療:M&Aディール及び事業提携情報
    Summary Xbrane Biopharma AB (Xbrane), formerly Xbrane Bioscience AB is a biopharmaceutical company that develops and manufactures complex generic products. The company's product portfolio includes biosimilars and long acting injectables developed for people suffering from critical diseases. It combi …
  • Damodar Valley Corp:企業の戦略的SWOT分析
    Damodar Valley Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Bone Therapeutics SA (BOTHE):医療機器:M&Aディール及び事業提携情報
    Summary Bone Therapeutics SA (Bone Therapeutics) is a cell therapy company that develops autologous and allogeneic cell therapy products. The company offers pipeline products such as PREOB, an autologous osteoblastic cell therapy product used for the treatment of osteonecrosis and non-union fracture …
  • Euticals SpA-製薬・医療分野:企業M&A・提携分析
    Summary Euticals SpA (Euticals) is a chemical company that develops and supplies active pharmaceutical ingredients, fine chemicals and contract manufacturing. The company possess technologies and capabilities in the domains of fermentation and enzymatic chemistry; boronic acids, biaryls, grignards a …
  • Elektrani na Makedonija:企業の戦略的SWOT分析
    Elektrani na Makedonija - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Inovalon Holdings Inc (INOV):企業の財務・戦略的SWOT分析
    Summary Inovalon Holdings Inc (Inovalon), formerly MedAssurant Inc is a technology company that provides cloud-based platforms for healthcare industry. The company designs, develops and distributes software tools to provide healthcare and financial improvement solutions. It provides data driven solu …
  • MediciNova Inc (MNOV):製薬・医療:M&Aディール及び事業提携情報
    Summary MediciNova Inc (MediciNova) focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs for the treatment of fibrotic diseases; neurological disorders; and …
  • Sumatec Resources Bhd (SUMATEC):石油・ガス:M&Aディール及び事業提携情報
    Summary Sumatec Resources Bhd (Sumatec) is an oilfield service provider that offers of construction and drilling services to the oil and gas industry. The company’s services include engineering and construction for oil and gas facilities, oil and gas assets development, supply and management of onsh …
  • Edion Corporation (2730):企業の財務・戦略的SWOT分析
    Edion Corporation (2730) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Nidek Co Ltd:企業の戦略的SWOT分析
    Nidek Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Fresenius Medical Care AG & Co KGaA (FME):企業の財務・戦略的SWOT分析
    Fresenius Medical Care AG & Co KGaA (FME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • General Electric Co (GE)-エネルギー分野:企業M&A・提携分析
    Summary General Electric Company (GE) is a digital industrial company. It offers a range of industrial, infrastructure and financial services globally. The company offers a range of products and services from aircraft engines, power generation and oil and gas production equipment to medical imaging, …
  • Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Encycle Corp:電力:M&Aディール及び事業提携情報
    Summary Encycle Corp (Encycle), formerly REGEN Energy Inc, is a clean technology company that develops energy management technology based on swarm logic concepts. The company’s solutions include wireless automated demand management and demand response solutions and swarm energy management solutions. …
  • Dexcel PT Israel Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Dexcel PT Israel Ltd (Dexcel Pharma), a subsidiary of Dexcel PT Holdings Ltd, develops, manufactures and markets branded and generic pharmaceuticals. Its featured products include PerioChip (chlorhexidine gluconate), a non-antibiotic adjunct treatment for scaling and root planing and adult p …
  • IDT Biologika GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary IDT Biologika GmbH (IDT Biologika), a subsidiary of Klocke Pharma-Service GmbH, is a vaccines and pharmaceuticals manufacturer. The company offers contract manufacturing services. It provides integrated development and manufacturing services in four major areas of animal health, vaccines, ph …
  • SeaBird Exploration PLC (SBX)-石油・ガス分野:企業M&A・提携分析
    Summary SeaBird Exploration Ltd (SeaBird) is an oil and gas company that provides marine 2D and 3D seismic data services. The company’s services include 2D seismic acquisition, 3D and 3D shallow water acquisition and source vessel. Its source vessels offers services such as conventional undershoots, …
  • Petra Energy Bhd (PENERGY):石油・ガス:M&Aディール及び事業提携情報
    Summary Petra Energy Bhd (Petra Energy) is an integrated brown field service provider for the upstream oil and gas industry. The company offers services such as designing, procurement, engineering, installation, fabrication, commissioning, maintenance, construction and project management. It also pr …
  • Cobb Electric Membership Corporation:企業の戦略的SWOT分析
    Cobb Electric Membership Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Tesaro Inc (TSRO)-医療機器分野:企業M&A・提携分析
    Summary Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates, comprising rolapitant, niraparib, and the product candidates under its immuno-oncology platform. VARUBI, the company’s first commercial product is …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆